The paper shows how patient-focused methodologies, enabling technologies and emerging biopharma ecosystems will deliver a step change in the number of treatments needed for the estimated 400 million people living with a rare condition.
Download the white paper below to explore these topics and access exclusive insights from our interviewed experts: Elin Haf Davies (Aparito), Dr Jamie Duckers (Rare Disease Wales), Dave Latshaw (BioPhy), Vaughan Gething (Wales' Economy Minister), Gareth Healey (Life Sciences Hub Wales), and Andrea Tithecott and Christina Sochacki (Al Tamim & Company).
With thanks to the authors, Jordan Taylor and Julie Walters.
About Ambrose Healthcare (www.ambrosehc.com)
Ambrose Healthcare is a specialist pharmaceutical company, developing new treatments for rare diseases, and for patients managed in hospitals and specialist care.
The company has an internationally experienced leadership team with deep knowledge of the pharmaceutical industry and a track record of success.
Ambrose Healthcare is developing a portfolio of commercial and clinical-stage therapeutic assets through acquisition, licensing and collaborations.
For more information, please contact:
Georgia Wilson, Chief of Staff.
Email: georgia.wilson@ambrosehc.com